First human test for new liver cancer treatment combo
NCT ID NCT07478302
Summary
This is an early-stage study to test the safety, dosing, and initial effectiveness of a new drug called SHR-2524 when combined with an existing cancer drug, bevacizumab. It will involve 36 adults with advanced liver cancer who have not yet received systemic treatment. The main goals are to understand how the body processes the drugs and to monitor for side effects, while also looking for early signs that the treatment can control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, 350002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.